Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I

Approximately 15% of acral and mucous melanomas carry activating mutations in KIT oncogene. There is a diversity of spectrum of KIT mutations, with some of them rendering tumors responsive to imatinib, while others being imatinib-resistant or not studied yet. Here we present an acral melanoma patien...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Case Rep Oncol
Autors principals: Orlova, Kristina V., Yanus, Grigory A., Aleksakhina, Svetlana N., Venina, Aigul R., Iyevleva, Aglaya G., Demidov, Lev V., Imyanitov, Evgeny N.
Format: Artigo
Idioma:Inglês
Publicat: S. Karger AG 2019
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6477486/
https://ncbi.nlm.nih.gov/pubmed/31043947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000495782
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars